BioCryst Pharmaceuticals (BCRX) News
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BCRX news summary
We found 11 recent headlines mentioning BioCryst Pharmaceuticals (BCRX): 0 in the past week and 7 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, BCRX is down 1.37% at $7.22. The most recent story, "BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting", was published by GlobeNewswire on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest BioCryst Pharmaceuticals headlines
- BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting— Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy —GlobeNewswire
- The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and MadrigalTGTX, BCRX, INSM and MDGL are expanding commercial reach through rising therapy sales, broader patient access and potential new indications.NasdaqBCRX, INSM, TGTX, MDGL
- 4 Commercial-Stage Biotechs Poised for Sustained Revenue GrowthTGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.NasdaqBCRX, INSM, TGTX, MDGL
- BioCryst to Present at Upcoming Investor ConferencesRESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:GlobeNewswire
- BioCryst (BCRX) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- BioCryst Reports Third Quarter 2026 Financial ResultsBioCryst Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2026, delivering Total net revenue of $180.3 million and ORLADEYO net revenue of $174.8 million.…Nasdaq
- BioCryst Reports Third Quarter 2026 Financial Results— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million —GlobeNewswire
- BioCryst to Report Third Quarter 2026 Financial Results on November 4RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on…GlobeNewswire
- BioCryst Wins FDA Approval For Orladeyo Oral Pellets In HAE Patients Aged 12 And Older(RTTNews) - BioCryst Pharmaceuticals Inc. (BCRX) said Wednesday that the U.S. Food and Drug Administration has approved its oral pellet formulation of Orladeyo for preventing hereditary angioedema…NasdaqBCRX, DDS
- BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences—GlobeNewswire
- Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal(RTTNews) - This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing collaborations,…NasdaqAMGN, AZN, BCRX, BHVN